reason report
rais estim reflect still strong growth momentum pt
bottom line continu glucos monitor survey
publish today rais sale estim
-- y/i previous -- better
reflect still strong growth momentum despit on-going mp
libr launch assum basic flat commerci
new patient add vs declin previous survey clearli
suggest still strong adopt trend particularli type patient
popul sale estim move higher
y/i previous ep estim move
admittedli too-high prior estim
assum margin pressur due project sensor price
cut overal continu believ sale guidanc
y/i mid-point conserv leav room
potenti upsid now-high estim come
ahead street survey clearli suggest still strong
adopt momentum believ share
continu move meaning higher current level
investor competit concern eas street number continu
move
reiter op rate pt pt -- previous
-- appli ev/sal higher estim
share current trade sale estim
basic in-lin compar small-cap med-tech compani
still reflect
notabl multipl contract premium level
trade previous investor visibl
achiev top-tier growth timelin lower-cost verili
product exist competit overhang share
lift view
medic suppli devic
sale
compani inform leerink partner llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea --
essenti cgm-augment insulin pump system automat accur dose
patient new patient adopt momentum -- set launch -- like
sustain sale growth near medium term despit competit headwind continu
product evolut includ possibl much less-costli type product conjunct
googl partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share
current trade sale estim basic line
compar small-cap med-tech compani still
reflect notabl multipl contract premium level trade
previous investor visibl achiev top-tier growth
timelin lower-cost verili product exist competit overhang share
lift view acknowledg take play
back half stori ultim believ share warrant least
modest premium small-cap med-tech stock univers given massiv
highli under-penetrated total address market per estim consist
upsid potenti top-tier growth outlook longer term
risk includ failur success secur fda approv time manner
failur continu evolv sensor technolog includ verili product type patient
toward sensor-integr pump potenti price pressur increas competit
potenti product recal reimburs issu
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
research develop expens
sg sale
 sale
oper expens sale
compani report leerink partner estim
